Canine Leishmaniasis Management Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2017 to 2021 and Forecast 2022 to 2028

$ PRICE - $ 3,000.00$ 8,900.00

Canine Leishmaniasis Management Market by Product Type (Canine leishmaniasis prevention, Canine leishmaniasis treatment), by Disease Type (Visceral leishmaniasis, Cutaneous leishmaniasis, Mucocutaneous leishmaniasis), by Route of Administration (Oral, Parenteral, Topical), by Distribution Channel (Veterinary clinics, Veterinary pharmacies, Online pharmacies, NGO’s, Others) and Geography

 

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail
SKU: N/A Category:

Report

Description

The canine leishmaniasis management market is growing at a significant CAGR of 9.2% during the forecast period 2022 to 2028 due to increase in adoption of canines. Canine leishmaniasis is a vector-borne disease caused by the Leishmania infantum and Leishmania chagasi. Canine leishmaniasis is transmitted through the infected Phlebotominae flies. The severity of the canine leishmaniasis leads to the death of animals and high risk of disease transmission in humans and other dogs.  The primary symptoms associated with the canine leishmaniasis include asthenia, anaemia, cachexia, weight loss, skin lesions, and muscular atrophy. In the later stage the symptoms like abnormal growth of nails, conjunctivitis, and renal failure may occur in the canines. The canine leishmaniasis can be prevented by administering the vaccines initially 3 doses with 3-week interval between them and an annual dose which increase the immunity in the canines. Global canine leishmaniasis management market is in the developing stage with several international players are actively involved in the development of formulations for the treatment and prevention of canine leishmaniasis. Increase in the research and development for canine leishmaniasis vaccines, product approval from various regulatory bodies such as EMEA and FDA, and launching of new products into the market might fuel the canine leishmaniasis management market over the forecast period. For instance, in March 2011, EMEA approved the marketing authorization in the Europe region for CaniLeish vaccine manufactured by Virbac S.A. Similarly, US Food and Drug Administration scientists are working with India and Brazil scientists for the development of a non-virulent vaccine to treat visceral leishmaniasis in canines.

Canine Leishmaniasis Management Market

MARKET SUMMARY
-
9.2% CAGR
  • Study Period– 2022 – 2028
  • Base Year– 2021
  • CAGR– 9.2%
  • Largest Market– Europe
  • Fastest Growing Market– Asia Pacific

Canine Leishmaniasis Management Market

  • The global Canine Leishmaniasis Management Market report gives comprehensive outlook on Canine Leishmaniasis Management Market across the globe with special emphasis on key regions such as Asia Pacific, North America, Europe, Latin America, and Middle East and Africa.
  • The report on global Canine Leishmaniasis Management Market gives historical, current, and future market sizes (US$ Mn) on the basis of product type, disease type, route of administration, distribution channel and Region.
Key Players
  • Zoetis, Inc. (Pfizer) (U.S)
  • Hertape Calier Saude Animal S.A. (Brazil)
  • Virbac AH Inc. (France)
  • Laboratories Leti (Spain)
  • Bioiberica S.A. (Spain)
Dynamics

Canine Leishmaniasis Management Market

A rise in the prevalence of canine Leishmania, increase in the research and development for new vaccines for canine leishmaniasis management, rise in the expenditure for animal welfare and wellness, and patent filings for the various canine leishmaniasis management formulations might fuel the canine leishmaniasis management market over the forecast years. However, stringent regulatory policies for the approval of new vaccines for the canine leishmaniasis management, storage of vaccines, lack of awareness regarding canine leishmaniasis management, increase in the canine culling process, and dearth of canine leishmaniasis management products in the market might hamper the canine leishmaniasis management market growth in the forecast years.


Europe got significant share

Canine Leishmaniasis Management Market

Geographically, canine leishmaniasis management market is segmented into the following regions Viz. Europe, North America, Asia Pacific, Middle East and Africa, and Latin America. Europe holds significant share in the global canine leishmaniasis management market owing to the presence of tropical and subtropical areas which are favourable for the growth of sand flies. Spain, France, Greece, Italy and some other European countries have the highest prevalence of canine leishmaniasis. Increase in the research and development for Leishmania vaccines, rise in the expenditure of animal welfare and growing awareness about the canine leishmaniasis treatment might bolster the market. Asia Pacific canine leishmania management market growth over the forecast years attributed to poor hygienic conditions in the rural area, increase in the canine adoption rate, and the environmental conditions that favour the growth of sand flies. Increase in the canine leishmaniasis prevalence rate majorly in India, China, Bangladesh, Saudi Arabia, and UAE might fuel the canine leishmaniasis management market. North America holds a reasonable share due to increase in the adoption rate of canines (according to American Pet Products Association, approximately 78 Mn canines were owned in the U.S.).

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Features of the Report

  • The report provides granular level information about the market size, regional market share, and forecast
  • The report covers in-detail insights about the competitor’s overview, key findings, and their key strategies
  • The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry
  • The report tracks recent innovations, key developments, and startup’s details that are working in the industry
  • The report provides plethora of information about market entry strategies, regulatory framework, and reimbursement scenario

Canine Leishmaniasis Management Market Segmentation


Location

GEOGRAPHY

Frequently Asked Questions

The canine leishmaniasis management market is projected to expand at a CAGR of 9.2% during the forecast period.

Zoetis, Inc. (Pfizer) (U.S), Hertape Calier Saude Animal S.A. (Brazil), Virbac AH Inc. (France), Laboratories Leti (Spain), Bioiberica S.A. (Spain)

Asia Pacific is the fastest-growing region for canine leishmaniasis management market


Report

Table Of Content

1. Executive Summary
2. Global Canine Leishmaniasis Management Market Introduction
2.1. Global Canine Leishmaniasis Management Market – Taxonomy
2.2. Global Canine Leishmaniasis Management Market –Definitions
2.2.1. By Product Type
2.2.2. By Disease
2.2.3. By Administration
2.2.4. By Distribution Channel
2.2.5. By Region
3. Global Canine Leishmaniasis Management Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Canine Leishmaniasis Management Market Dynamic Factors – Impact Analysis
3.6. Global Canine Leishmaniasis Management Market – Competition Landscape
4. Global Canine Leishmaniasis Management Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028
4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5. Global Canine Leishmaniasis Management Market, By Product Type, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.1. Vaccines
5.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) & (Volume, Units)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Antibiotics
5.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Polyene antibiotics (Amphotericin B)
5.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. Marbofloxacin
5.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
5.5. Miltefosine
5.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.5.3. Market Opportunity Analysis
5.6. Meglumine Antimoniate
5.6.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.6.3. Market Opportunity Analysis
5.7. Pentavalent antimonials
5.7.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.7.3. Market Opportunity Analysis
5.8. Allopurinol combinations
5.8.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.8.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.8.3. Market Opportunity Analysis
5.9. Paromomycin
5.9.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.9.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.9.3. Market Opportunity Analysis
6. Global Canine Leishmaniasis Management Market Forecast, By Disease, 2017 – 2021 and Forecast, 2022 – 2028
6.1. Visceral leishmaniasis
6.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Cutaneous leishmaniasis
6.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Mucocutaneous leishmaniasis
6.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
7. Global Canine Leishmaniasis Management Market Forecast, By Administration, 2017 – 2021 and Forecast, 2022 – 2028
7.1. Oral
7.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Parenteral
7.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Topical
7.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
1. Executive Summary
2. Global Canine Leishmaniasis Management Market Introduction
2.1. Global Canine Leishmaniasis Management Market – Taxonomy
2.2. Global Canine Leishmaniasis Management Market –Definitions
2.2.1. By Product Type
2.2.2. By Disease
2.2.3. By Administration
2.2.4. By Distribution Channel
2.2.5. By Region
3. Global Canine Leishmaniasis Management Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Canine Leishmaniasis Management Market Dynamic Factors – Impact Analysis
3.6. Global Canine Leishmaniasis Management Market – Competition Landscape
4. Global Canine Leishmaniasis Management Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028
4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5. Global Canine Leishmaniasis Management Market, By Product Type, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.1. Vaccines
5.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) & (Volume, Units)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Antibiotics
5.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Polyene antibiotics (Amphotericin B)
5.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. Marbofloxacin
5.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
5.5. Miltefosine
5.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.5.3. Market Opportunity Analysis
5.6. Meglumine Antimoniate
5.6.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.6.3. Market Opportunity Analysis
5.7. Pentavalent antimonials
5.7.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.7.3. Market Opportunity Analysis
5.8. Allopurinol combinations
5.8.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.8.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.8.3. Market Opportunity Analysis
5.9. Paromomycin
5.9.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.9.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.9.3. Market Opportunity Analysis
6. Global Canine Leishmaniasis Management Market Forecast, By Disease, 2017 – 2021 and Forecast, 2022 – 2028
6.1. Visceral leishmaniasis
6.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Cutaneous leishmaniasis
6.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Mucocutaneous leishmaniasis
6.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
7. Global Canine Leishmaniasis Management Market Forecast, By Administration, 2017 – 2021 and Forecast, 2022 – 2028
7.1. Oral
7.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Parenteral
7.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Topical
7.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
8. Global Canine Leishmaniasis Management Market Forecast, By Application, 2017 – 2021 and Forecast, 2022 – 2028
8.1. Veterinary Clinics
8.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Veterinary Pharmacies
8.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Online Pharmacies
8.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
8.4. NGO’s
8.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.4.3. Market Opportunity Analysis
8.5. Others
8.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.5.3. Market Opportunity Analysis
9. Global Canine Leishmaniasis Management Market Forecast, By Region, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
9.1. North America
9.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.1.3. Market Opportunity Analysis
9.2. Europe
9.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.2.3. Market Opportunity Analysis
9.3. Asia-Pacific
9.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.3.3. Market Opportunity Analysis
9.4. Latin America
9.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
9.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.4.3. Market Opportunity Analysis
9.5. Middle East and Africa
9.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
9.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.5.3. Market Opportunity Analysis
9.6. Global Canine Leishmaniasis Management Market – Opportunity Analysis Index, By Product Type, By Disease, By Administration, By Distribution Channel and Region 2022 – 2028
10. North America Canine Leishmaniasis Management Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
10.1. Product Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by (Revenue, USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1. Vaccines
10.1.2. Antibiotics
10.1.3. Polyene Antibiotics (Amphotericin B)
10.1.4. Marbofloxacin
10.1.5. Miltefosine
10.1.6. Meglumine Antimoniate
10.1.7. Pentavalent Antimonials
10.1.8. Allopurinol Combinations
10.1.9. Paromomycin
10.1.10. Others
10.2. Disease Analysis 2017 – 2021 and Forecast 2022 – 2028 by (Revenue, USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.2.1. Visceral leishmaniasis
10.2.2. Cutaneous leishmaniasis
10.2.3. Mucocutaneous leishmaniasis
10.3. Administration Analysis 2017 – 2021 and Forecast 2022 – 2028 by (Revenue, USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.3.1. Oral
10.3.2. Parenteral
10.3.3. TopicalSkin
10.4. Distribution Channel Analysis 2017 – 2021 and Forecast 2022 – 2028 by (Revenue, USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.4.1. Veterinary Clinics
10.4.2. Veterinary Pharmacies
10.4.3. Online Pharmacies
10.4.4. NGO’s
10.4.5. Others
10.5. Country Analysis 2017 – 2021 and Forecast 2022 – 2028  by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
10.5.1. U.S.
10.5.2. Canada
10.6. North America Canine Leishmaniasis Management Market – Opportunity Analysis Index, By Product Type, By Disease, By Administration, By Distribution Channel and Country, 2022 – 2028
10.7. North America Canine Leishmaniasis Management Market Dynamics – Trends
11. Europe Canine Leishmaniasis Management Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
11.1. Product Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by (Revenue, USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1. Vaccines
11.1.2. Antibiotics
11.1.3. Polyene Antibiotics (Amphotericin B)
11.1.4. Marbofloxacin
11.1.5. Miltefosine
11.1.6. Meglumine Antimoniate
11.1.7. Pentavalent Antimonials
11.1.8. Allopurinol Combinations
11.1.9. Paromomycin
11.1.10. Others
11.2. Disease Analysis 2017 – 2021 and Forecast 2022 – 2028 by (Revenue, USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.2.1. Visceral leishmaniasis
11.2.2. Cutaneous leishmaniasis
11.2.3. Mucocutaneous leishmaniasis
11.3. Administration Analysis 2017 – 2021 and Forecast 2022 – 2028 by (Revenue, USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.3.1. Oral
11.3.2. Parenteral
11.3.3. TopicalSkin
11.4. Distribution Channel Analysis 2017 – 2021 and Forecast 2022 – 2028 by (Revenue, USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.4.1. Veterinary Clinics
11.4.2. Veterinary Pharmacies
11.4.3. Online Pharmacies
11.4.4. NGO’s
11.4.5. Others
11.5. Country Analysis 2017 – 2021 and Forecast 2022 – 2028  by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
11.5.1. Germany
11.5.2. UK
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Russia
11.5.7. Poland
11.5.8. Rest of Europe
11.6. Europe Canine Leishmaniasis Management Market – Opportunity Analysis Index, By Product Type, By Disease, By Administration, By Distribution Channel and Country, 2022 – 2028
11.7. Europe Canine Leishmaniasis Management Market Dynamics – Trends
12. Asia-Pacific Canine Leishmaniasis Management Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
12.1. Product Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by (Revenue, USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1. Vaccines
12.1.2. Antibiotics
12.1.3. Polyene Antibiotics (Amphotericin B)
12.1.4. Marbofloxacin
12.1.5. Miltefosine
12.1.6. Meglumine Antimoniate
12.1.7. Pentavalent Antimonials
12.1.8. Allopurinol Combinations
12.1.9. Paromomycin
12.1.10. Others
12.2. Disease Analysis 2017 – 2021 and Forecast 2022 – 2028 by (Revenue, USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.2.1. Visceral leishmaniasis
12.2.2. Cutaneous leishmaniasis
12.2.3. Mucocutaneous leishmaniasis
12.3. Administration Analysis 2017 – 2021 and Forecast 2022 – 2028 by (Revenue, USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.3.1. Oral
12.3.2. Parenteral
12.3.3. TopicalSkin
12.4. Distribution Channel Analysis 2017 – 2021 and Forecast 2022 – 2028 by (Revenue, USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.4.1. Veterinary Clinics
12.4.2. Veterinary Pharmacies
12.4.3. Online Pharmacies
12.4.4. NGO’s
12.4.5. Others
12.5. Country Analysis 2017 – 2021 and Forecast 2022 – 2028  by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
12.5.1. Japan
12.5.2. China
12.5.3. India
12.5.4. ASEAN
12.5.5. Australia & New Zealand
12.5.6. Rest of Asia-Pacific
12.6. Asia-Pacific Canine Leishmaniasis Management Market – Opportunity Analysis Index, By Product Type, By Disease, By Administration, By Distribution Channel and Country, 2022 – 2028
12.7. Asia-Pacific Canine Leishmaniasis Management Market Dynamics – Trends
13. Latin America Canine Leishmaniasis Management Market Analysis, 2017 – 2021 and Forecast, 2020 – 2026
13.1. Product Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by (Revenue, USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.1. Vaccines
13.1.2. Antibiotics
13.1.3. Polyene Antibiotics (Amphotericin B)
13.1.4. Marbofloxacin
13.1.5. Miltefosine
13.1.6. Meglumine Antimoniate
13.1.7. Pentavalent Antimonials
13.1.8. Allopurinol Combinations
13.1.9. Paromomycin
13.1.10. Others
13.2. Disease Analysis 2017 – 2021 and Forecast 2022 – 2028 by (Revenue, USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.2.1. Visceral leishmaniasis
13.2.2. Cutaneous leishmaniasis
13.2.3. Mucocutaneous leishmaniasis
13.3. Administration Analysis 2017 – 2021 and Forecast 2022 – 2028 by (Revenue, USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.3.1. Oral
13.3.2. Parenteral
13.3.3. TopicalSkin
13.4. Distribution Channel Analysis 2017 – 2021 and Forecast 2022 – 2028 by (Revenue, USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.4.1. Veterinary Clinics
13.4.2. Veterinary Pharmacies
13.4.3. Online Pharmacies
13.4.4. NGO’s
13.4.5. Others
13.5. Country Analysis 2017 – 2021 and Forecast 2022 – 2028  by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Argentina
13.5.4. Rest of Latin America
13.6. Latin America Canine Leishmaniasis Management Market – Opportunity Analysis Index, By Product Type, By Disease, By Administration, By Distribution Channel and Country, 2022 – 2028
13.7. Latin America Canine Leishmaniasis Management Market Dynamics – Trends
14. Middle East and Africa Canine Leishmaniasis Management Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
14.1. Product Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by (Revenue, USD Mn), Y-o-Y Growth (%), and Market Share (%)
14.1.1. Vaccines
14.1.2. Antibiotics
14.1.3. Polyene Antibiotics (Amphotericin B)
14.1.4. Marbofloxacin
14.1.5. Miltefosine
14.1.6. Meglumine Antimoniate
14.1.7. Pentavalent Antimonials
14.1.8. Allopurinol Combinations
14.1.9. Paromomycin
14.1.10. Others
14.2. Disease Analysis 2017 – 2021 and Forecast 2022 – 2028 by (Revenue, USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.2.1. Visceral leishmaniasis
14.2.2. Cutaneous leishmaniasis
14.2.3. Mucocutaneous leishmaniasis
14.3. Administration Analysis 2017 – 2021 and Forecast 2022 – 2028 by (Revenue, USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.3.1. Oral
14.3.2. Parenteral
14.3.3. TopicalSkin
14.4. Distribution Channel Analysis 2017 – 2021 and Forecast 2022 – 2028 by (Revenue, USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.4.1. Veterinary Clinics
14.4.2. Veterinary Pharmacies
14.4.3. Online Pharmacies
14.4.4. NGO’s
14.4.5. Others
14.5. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
14.5.1. Gulf Cooperation Council (GCC) Countries
14.5.2. Israel
14.5.3. South Africa
14.5.4. Rest of MEA
14.6. MEA Canine Leishmaniasis Management Market – Opportunity Analysis Index, By Product Type, By Disease, By Administration, By Distribution Channel and Country, 2022 – 2028
14.7. MEA Canine Leishmaniasis Management Market Dynamics – Trends
15. Competition Landscape
15.1. Strategic Dashboard of Top Market Players
15.2. Company Profiles (Introduction, Financial Analysis, Product Type & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
15.2.1. Zoetis, Inc. (Pfizer) (U.S)
15.2.2. Ceva Santé Animale (Hertape Calier Saude Animal S.A)
15.2.3. Virbac AH Inc. (France)
15.2.4. Laboratories Leti (Spain)
15.2.5. Bioiberica S.A. (Spain)
15.2.6. Sanofi S.A. (France)
16. Research Methodology
17. Key Assumptions and Acronyms
8.1. Veterinary Clinics
8.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Veterinary Pharmacies
8.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Online Pharmacies
8.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
8.4. NGO’s
8.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.4.3. Market Opportunity Analysis
8.5. Others
8.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.5.3. Market Opportunity Analysis
9. Global Canine Leishmaniasis Management Market Forecast, By Region, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
9.1. North America
9.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.1.3. Market Opportunity Analysis
9.2. Europe
9.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.2.3. Market Opportunity Analysis
9.3. Asia-Pacific
9.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.3.3. Market Opportunity Analysis
9.4. Latin America
9.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
9.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.4.3. Market Opportunity Analysis
9.5. Middle East and Africa
9.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
9.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.5.3. Market Opportunity Analysis
9.6. Global Canine Leishmaniasis Management Market – Opportunity Analysis Index, By Product Type, By Disease, By Administration, By Distribution Channel and Region 2022 – 2028
10. North America Canine Leishmaniasis Management Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
10.1. Product Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by (Revenue, USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1. Vaccines
10.1.2. Antibiotics
10.1.3. Polyene Antibiotics (Amphotericin B)
10.1.4. Marbofloxacin
10.1.5. Miltefosine
10.1.6. Meglumine Antimoniate
10.1.7. Pentavalent Antimonials
10.1.8. Allopurinol Combinations
10.1.9. Paromomycin
10.1.10. Others
10.2. Disease Analysis 2017 – 2021 and Forecast 2022 – 2028 by (Revenue, USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.2.1. Visceral leishmaniasis
10.2.2. Cutaneous leishmaniasis
10.2.3. Mucocutaneous leishmaniasis
10.3. Administration Analysis 2017 – 2021 and Forecast 2022 – 2028 by (Revenue, USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.3.1. Oral
10.3.2. Parenteral
10.3.3. TopicalSkin
10.4. Distribution Channel Analysis 2017 – 2021 and Forecast 2022 – 2028 by (Revenue, USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.4.1. Veterinary Clinics
10.4.2. Veterinary Pharmacies
10.4.3. Online Pharmacies
10.4.4. NGO’s
10.4.5. Others
10.5. Country Analysis 2017 – 2021 and Forecast 2022 – 2028  by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
10.5.1. U.S.
10.5.2. Canada
10.6. North America Canine Leishmaniasis Management Market – Opportunity Analysis Index, By Product Type, By Disease, By Administration, By Distribution Channel and Country, 2022 – 2028
10.7. North America Canine Leishmaniasis Management Market Dynamics – Trends
11. Europe Canine Leishmaniasis Management Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
11.1. Product Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by (Revenue, USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1. Vaccines
11.1.2. Antibiotics
11.1.3. Polyene Antibiotics (Amphotericin B)
11.1.4. Marbofloxacin
11.1.5. Miltefosine
11.1.6. Meglumine Antimoniate
11.1.7. Pentavalent Antimonials
11.1.8. Allopurinol Combinations
11.1.9. Paromomycin
11.1.10. Others
11.2. Disease Analysis 2017 – 2021 and Forecast 2022 – 2028 by (Revenue, USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.2.1. Visceral leishmaniasis
11.2.2. Cutaneous leishmaniasis
11.2.3. Mucocutaneous leishmaniasis
11.3. Administration Analysis 2017 – 2021 and Forecast 2022 – 2028 by (Revenue, USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.3.1. Oral
11.3.2. Parenteral
11.3.3. TopicalSkin
11.4. Distribution Channel Analysis 2017 – 2021 and Forecast 2022 – 2028 by (Revenue, USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.4.1. Veterinary Clinics
11.4.2. Veterinary Pharmacies
11.4.3. Online Pharmacies
11.4.4. NGO’s
11.4.5. Others
11.5. Country Analysis 2017 – 2021 and Forecast 2022 – 2028  by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
11.5.1. Germany
11.5.2. UK
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Russia
11.5.7. Poland
11.5.8. Rest of Europe
11.6. Europe Canine Leishmaniasis Management Market – Opportunity Analysis Index, By Product Type, By Disease, By Administration, By Distribution Channel and Country, 2022 – 2028
11.7. Europe Canine Leishmaniasis Management Market Dynamics – Trends
12. Asia-Pacific Canine Leishmaniasis Management Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
12.1. Product Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by (Revenue, USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1. Vaccines
12.1.2. Antibiotics
12.1.3. Polyene Antibiotics (Amphotericin B)
12.1.4. Marbofloxacin
12.1.5. Miltefosine
12.1.6. Meglumine Antimoniate
12.1.7. Pentavalent Antimonials
12.1.8. Allopurinol Combinations
12.1.9. Paromomycin
12.1.10. Others
12.2. Disease Analysis 2017 – 2021 and Forecast 2022 – 2028 by (Revenue, USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.2.1. Visceral leishmaniasis
12.2.2. Cutaneous leishmaniasis
12.2.3. Mucocutaneous leishmaniasis
12.3. Administration Analysis 2017 – 2021 and Forecast 2022 – 2028 by (Revenue, USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.3.1. Oral
12.3.2. Parenteral
12.3.3. TopicalSkin
12.4. Distribution Channel Analysis 2017 – 2021 and Forecast 2022 – 2028 by (Revenue, USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.4.1. Veterinary Clinics
12.4.2. Veterinary Pharmacies
12.4.3. Online Pharmacies
12.4.4. NGO’s
12.4.5. Others
12.5. Country Analysis 2017 – 2021 and Forecast 2022 – 2028  by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
12.5.1. Japan
12.5.2. China
12.5.3. India
12.5.4. ASEAN
12.5.5. Australia & New Zealand
12.5.6. Rest of Asia-Pacific
12.6. Asia-Pacific Canine Leishmaniasis Management Market – Opportunity Analysis Index, By Product Type, By Disease, By Administration, By Distribution Channel and Country, 2022 – 2028
12.7. Asia-Pacific Canine Leishmaniasis Management Market Dynamics – Trends
13. Latin America Canine Leishmaniasis Management Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028
13.1. Product Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by (Revenue, USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.1. Vaccines
13.1.2. Antibiotics
13.1.3. Polyene Antibiotics (Amphotericin B)
13.1.4. Marbofloxacin
13.1.5. Miltefosine
13.1.6. Meglumine Antimoniate
13.1.7. Pentavalent Antimonials
13.1.8. Allopurinol Combinations
13.1.9. Paromomycin
13.1.10. Others
13.2. Disease Analysis 2017 – 2021 and Forecast 2022 – 2028 by (Revenue, USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.2.1. Visceral leishmaniasis
13.2.2. Cutaneous leishmaniasis
13.2.3. Mucocutaneous leishmaniasis
13.3. Administration Analysis 2017 – 2021 and Forecast 2022 – 2028 by (Revenue, USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.3.1. Oral
13.3.2. Parenteral
13.3.3. TopicalSkin
13.4. Distribution Channel Analysis 2017 – 2021 and Forecast 2022 – 2028 by (Revenue, USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.4.1. Veterinary Clinics
13.4.2. Veterinary Pharmacies
13.4.3. Online Pharmacies
13.4.4. NGO’s
13.4.5. Others
13.5. Country Analysis 2017 – 2021 and Forecast 2022 – 2028  by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Argentina
13.5.4. Rest of Latin America
13.6. Latin America Canine Leishmaniasis Management Market – Opportunity Analysis Index, By Product Type, By Disease, By Administration, By Distribution Channel and Country, 2022 – 2028
13.7. Latin America Canine Leishmaniasis Management Market Dynamics – Trends
14. Middle East and Africa Canine Leishmaniasis Management Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
14.1. Product Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by (Revenue, USD Mn), Y-o-Y Growth (%), and Market Share (%)
14.1.1. Vaccines
14.1.2. Antibiotics
14.1.3. Polyene Antibiotics (Amphotericin B)
14.1.4. Marbofloxacin
14.1.5. Miltefosine
14.1.6. Meglumine Antimoniate
14.1.7. Pentavalent Antimonials
14.1.8. Allopurinol Combinations
14.1.9. Paromomycin
14.1.10. Others
14.2. Disease Analysis 2017 – 2021 and Forecast 2022 – 2028 by (Revenue, USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.2.1. Visceral leishmaniasis
14.2.2. Cutaneous leishmaniasis
14.2.3. Mucocutaneous leishmaniasis
14.3. Administration Analysis 2017 – 2021 and Forecast 2022 – 2028 by (Revenue, USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.3.1. Oral
14.3.2. Parenteral
14.3.3. TopicalSkin
14.4. Distribution Channel Analysis 2017 – 2021 and Forecast 2022 – 2028 by (Revenue, USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.4.1. Veterinary Clinics
14.4.2. Veterinary Pharmacies
14.4.3. Online Pharmacies
14.4.4. NGO’s
14.4.5. Others
14.5. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
14.5.1. Gulf Cooperation Council (GCC) Countries
14.5.2. Israel
14.5.3. South Africa
14.5.4. Rest of MEA
14.6. MEA Canine Leishmaniasis Management Market – Opportunity Analysis Index, By Product Type, By Disease, By Administration, By Distribution Channel and Country, 2022 – 2028
14.7. MEA Canine Leishmaniasis Management Market Dynamics – Trends
15. Competition Landscape 
15.1. Strategic Dashboard of Top Market Players
15.2. Company Profiles (Introduction, Financial Analysis, Product Type & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
15.2.1. Zoetis, Inc. (Pfizer) (U.S)
15.2.2. Ceva Santé Animale (Hertape Calier Saude Animal S.A)
15.2.3. Virbac AH Inc. (France)
15.2.4. Laboratories Leti (Spain)
15.2.5. Bioiberica S.A. (Spain)
15.2.6. Sanofi S.A. (France)
16. Research Methodology
17. Key Assumptions and Acronyms

Report

Company Profile

  •  Zoetis, Inc. (Pfizer) (U.S)
  • Hertape Calier Saude Animal S.A. (Brazil)
  • Virbac AH Inc. (France)
  • Laboratories Leti (Spain)
  • Bioiberica S.A. (Spain)
  • Sanofi S.A. (France)

Description

The canine leishmaniasis management market is growing at a significant CAGR of 9.2% during the forecast period 2022 to 2028 due to increase in adoption of canines. Canine leishmaniasis is a vector-borne disease caused by the Leishmania infantum and Leishmania chagasi. Canine leishmaniasis is transmitted through the infected Phlebotominae flies. The severity of the canine leishmaniasis leads to the death of animals and high risk of disease transmission in humans and other dogs.  The primary symptoms associated with the canine leishmaniasis include asthenia, anaemia, cachexia, weight loss, skin lesions, and muscular atrophy. In the later stage the symptoms like abnormal growth of nails, conjunctivitis, and renal failure may occur in the canines. The canine leishmaniasis can be prevented by administering the vaccines initially 3 doses with 3-week interval between them and an annual dose which increase the immunity in the canines. Global canine leishmaniasis management market is in the developing stage with several international players are actively involved in the development of formulations for the treatment and prevention of canine leishmaniasis. Increase in the research and development for canine leishmaniasis vaccines, product approval from various regulatory bodies such as EMEA and FDA, and launching of new products into the market might fuel the canine leishmaniasis management market over the forecast period. For instance, in March 2011, EMEA approved the marketing authorization in the Europe region for CaniLeish vaccine manufactured by Virbac S.A. Similarly, US Food and Drug Administration scientists are working with India and Brazil scientists for the development of a non-virulent vaccine to treat visceral leishmaniasis in canines.

ASIA PACIFIC OFFICE

Precision Business Insights, 5th Floor, Mohan’s Elite, Opp : Bharat Petroleum Pump, Khanamet Road, Hitech City, Hyderabad – 500084

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX